Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999993 | 0.78 | DYRK1A (0.51) | POLBSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL31000020 | 0.78 | CDK2 (0.45) | POLBHPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4884039 | 0.78 | TP53 (0.45) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL9770215 | 0.75 | ALDH1A1 (0.65) | MGLLPOLBSMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL9170568 | 0.73 | EPHX1 (0.67) | POLBSMN1; SMN2EPHX1ALDH1A1HTT | |
| SCHEMBL8363843 | 0.73 | MAPT (0.42) | POLBSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL30999992 | 0.72 | CDK2 (0.66) | HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL13202968 | 0.70 | KAT2B (0.40) | POLBHPGDSMN1; SMN2RIPK1ALDH1A1 | |
| SCHEMBL17234004 | 0.69 | RAB9A (0.41) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11859468 | 0.69 | SMN1; SMN2 (0.58) | MGLLPOLBHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921404-B2 | Azole derivatives in the form of lipase and phospholipase inhibitors | SANOFI (FR) | 2014-12-30 | — | — | US | disclosed |
| US-20080090867-A1 | Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090867-A1 | Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example | FABP4, GPR119, LIPE | MGLL 30/4885TBXA2R 779/4885SLC6A2 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.